Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: Hutchmed - You Need To See This

3 China Stocks to Watch in May

Recent years have been challenging for Chinese stocks, but the outlook is brightening. With a newfound resilience in risk appetite and a more favorable investment climate, it could be wise to keep a watchful eye on Chinese stocks Waterdrop (WDH), HUTCHMED (HCM), and Trip.com Group (TCOM) that seem poised for…

3 China Stocks to Accelerate Your Portfolio Gains

3 China Stocks to Accelerate Your Portfolio Gains

The Chinese economy is showing signs of recovery as its economy grew faster than expectations. Moreover, proactive government measures are expected to stimulate further future economic growth. Amid this backdrop, investors could look to add fundamentally strong Chinese stocks: Trip.com Group (TCOM), HUTCHMED (China) (HCM), and JD.com (JD). Keep reading.

3 Top China Picks for May With Strong Buy Signals

3 Top China Picks for May With Strong Buy Signals

Despite the real estate industry crisis and other headwinds, the Chinese economy beats expectations to grow 5.3% in the first quarter, positioning it for future growth. Thus, top China stocks HUTCHMED (HCM), Autohome (ATHM), and Youdao (DAO) could be strong buys in May. Keep reading….

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Recap of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ:RLMD) lead asset REL-1017 as a monotherapy for the treatment major depressive disorder (MDD). Relmada shares traded in a range of $26.02 to $27.96 on a day volume of 173.79 thousand shares, closed regular trading…

Recap of Monday's Biotech Catalysts - End Of the Day Summary

Kodiak Sciences Inc. (NASDAQ:KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion. Kodiak shares traded in a range of $10.02 to $11.79 on a day volume of 4.05 million shares, closed regular trading session…

U.S. FDA Rejects HUTCHMED's New Drug Application For Surufatinib In Neuroendocrine Tumors

HUTCHMED (China) Limited (Nasdaq: HCM) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for Surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors (NETs).

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it.

inkl

Read news from The Economist, FT, and more,
with one subscription

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework

According to a Bloomberg report, U.S. regulators could reportedly have full access to auditing reports from most of the 200-plus China-based companies listed in New York in mid-2022. In the drafting stage, the framework from the China Securities Regulatory Commission and other national agencies would let most Chinese firms keep their U.S.…

What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today

What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today

Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ:

Hutchmed Roils Markets With Changing of Its Guard, U.S. Delisting Threat

Hutchmed Roils Markets With Changing of Its Guard, U.S. Delisting Threat

Hutchmed Clocks Over 50% Jump In FY21 Sales Boosted By Three Oncology Drugs, Announces CEO Transition

Hutchmed Clocks Over 50% Jump In FY21 Sales Boosted By Three Oncology Drugs, Announces CEO Transition

Hutchmed (China) Limited (NASDAQ:HCM) reported FY21 sales of $356.1 million, up 56% Y/Y, driven by commercial progress on three in-house developed oncology drugs Elunate, Sulanda, and Orpathys. FY21 Oncology/Immunology consolidated revenues reached $119.6 million, up 296%, in line with the guidance of $110-130 million. Elunate revenues increased 168% to $53.5 million. Sulanda…

1

Organisations

Food and Drug Administration

BristolMyers Squibb Company

AstraZeneca Plc

BristolMyers Squibb

US Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

380,766 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play